These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 19589911

  • 1. High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease.
    Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S.
    Eur J Endocrinol; 2009 Oct; 161(4):553-9. PubMed ID: 19589911
    [Abstract] [Full Text] [Related]

  • 2. Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma.
    George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF, Lloyd RV, Meyer FB.
    Am J Surg Pathol; 2003 Oct; 27(10):1330-6. PubMed ID: 14508394
    [Abstract] [Full Text] [Related]

  • 3. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
    Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C, Knosp E.
    Cancer; 2009 Mar 01; 115(5):1070-80. PubMed ID: 19156926
    [Abstract] [Full Text] [Related]

  • 4. Long-term complete remission of Crooke's corticotropinoma after temozolomide treatment.
    Kurowska M, Tarach JS, Malicka J, Zieliński G, Maksymowicz M, Denew P.
    Endokrynol Pol; 2016 Mar 01; 67(5):526-533. PubMed ID: 27828691
    [Abstract] [Full Text] [Related]

  • 5. Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide.
    Tanaka S, Yamamoto M, Morita M, Takeno A, Kanazawa I, Yamaguchi T, Yamada S, Inoshita N, Oki Y, Kurosaki M, Sugimoto T.
    Endocr J; 2019 Aug 29; 66(8):701-708. PubMed ID: 31130573
    [Abstract] [Full Text] [Related]

  • 6. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
    Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H, Fukuhara N, Okada M, Nishioka H, Takeuchi Y, Komada M, Takeshita A, Yamada S.
    Eur J Endocrinol; 2016 Feb 29; 174(2):213-26. PubMed ID: 26578638
    [Abstract] [Full Text] [Related]

  • 7. Biochemical assessment of Cushing's disease in patients with corticotroph macroadenomas.
    Katznelson L, Bogan JS, Trob JR, Schoenfeld DA, Hedley-Whyte ET, Hsu DW, Zervas NT, Swearingen B, Sleeper M, Klibanski A.
    J Clin Endocrinol Metab; 1998 May 29; 83(5):1619-23. PubMed ID: 9589666
    [Abstract] [Full Text] [Related]

  • 8. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M.
    Pituitary; 2012 Sep 29; 15(3):276-87. PubMed ID: 22076588
    [Abstract] [Full Text] [Related]

  • 9. Temozolomide therapy for aggressive pituitary Crooke's cell corticotropinoma causing Cushing's Disease - a case report with literature review.
    Gilis-Januszewska A, Wilusz M, Pantofliński J, Turek-Jabrocka R, Sokołowski G, Sowa-Staszczak A, Kluczyński Ł, Pach D, Zieliński G, Hubalewska-Dydejczyk A.
    Endokrynol Pol; 2018 Sep 29; 69(3):306-312. PubMed ID: 29319131
    [Abstract] [Full Text] [Related]

  • 10. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
    Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T.
    J Clin Endocrinol Metab; 2010 Oct 29; 95(10):4592-9. PubMed ID: 20660056
    [Abstract] [Full Text] [Related]

  • 11. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas.
    Woo YS, Isidori AM, Wat WZ, Kaltsas GA, Afshar F, Sabin I, Jenkins PJ, Monson JP, Besser GM, Grossman AB.
    J Clin Endocrinol Metab; 2005 Aug 29; 90(8):4963-9. PubMed ID: 15886242
    [Abstract] [Full Text] [Related]

  • 12. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
    McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ.
    Clin Endocrinol (Oxf); 2009 Aug 29; 71(2):226-33. PubMed ID: 19067722
    [Abstract] [Full Text] [Related]

  • 13. Crooke's Changes In Cushing's Syndrome Depends on Degree of Hypercortisolism and Individual Susceptibility.
    Oldfield EH, Vance ML, Louis RG, Pledger CL, Jane JA, Lopes MB.
    J Clin Endocrinol Metab; 2015 Aug 29; 100(8):3165-71. PubMed ID: 26147609
    [Abstract] [Full Text] [Related]

  • 14. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
    Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M.
    Eur J Endocrinol; 2009 Oct 29; 161(4):631-7. PubMed ID: 19654234
    [Abstract] [Full Text] [Related]

  • 15. Use of temozolomide in aggressive pituitary tumors: case report.
    Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD.
    Neurosurgery; 2009 Apr 29; 64(4):E773-4; discussion E774. PubMed ID: 19349807
    [Abstract] [Full Text] [Related]

  • 16. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
    Micko ASG, Wöhrer A, Höftberger R, Vila G, Marosi C, Knosp E, Wolfsberger S.
    Pituitary; 2017 Dec 29; 20(6):643-653. PubMed ID: 28900805
    [Abstract] [Full Text] [Related]

  • 17. Surgical management of adrenocorticotropic hormone-secreting macroadenomas: outcome and challenges in patients with Cushing's disease or Nelson's syndrome.
    De Tommasi C, Vance ML, Okonkwo DO, Diallo A, Laws ER.
    J Neurosurg; 2005 Nov 29; 103(5):825-30. PubMed ID: 16304985
    [Abstract] [Full Text] [Related]

  • 18. MGMT expression in pituitary corticotroph adenomas and its relationship to clinical, pathological, and ultrastructural parameters in patients with Cushing's disease.
    Witek P, Maksymowicz M, Szamotulska K, Piaścik A, Wojciechowska-Luźniak A, Stasiewicz A, Witek J, Zieliński G.
    Folia Neuropathol; 2020 Nov 29; 58(4):357-364. PubMed ID: 33480240
    [Abstract] [Full Text] [Related]

  • 19. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
    Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M.
    Eur J Endocrinol; 2010 Dec 29; 163(6):843-51. PubMed ID: 20870708
    [Abstract] [Full Text] [Related]

  • 20. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
    Salehi F, Scheithauer BW, Kovacs K, Horvath E, Syro LV, Sharma S, Manoranjan B, Cusimano M.
    Neurosurgery; 2012 Feb 29; 70(2):491-6; discussion 496. PubMed ID: 21822153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.